TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1245165
Drug: 0.375 mg
Normalized name: vitamin A 0.375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375 mg digoxin with 1100 mg magnesium-aluminium-silicate-hydrate (n=4)
Study: 1245165
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg digoxin with 1000 mg dimagnesium-aluminium-trisilicate (n=5)
Study: 1245165
Drug: 0.375 mg
Normalized name: vitamin A 0.375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375 mg digoxin with 1000 mg dimagnesium-aluminium-trisilicate (n=5)
Study: 18700004
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment during an 8-week open-label, randomized, escalating dose Pharmacokinetic Phase
Study: 18700004
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment during a 16-week Long-Term Effectiveness Phase
Study: 18700004
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment during a 28-week double-blind Discontinuation Phase
Study: 18700004
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment during an 8-week open-label Restabilization Phase
Study: 18700004
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment during an 8-week double-blind, parallel-group, placebo-controlled Efficacy Phase
Study: 18700004
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment during an open-label Long-Term Effectiveness lasting either 16 or 24 weeks
Study: 15548718
Drug: Intradermal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal administration of granulocyte macrophage-colony stimulating factor around the excision site of stage I primary melanoma tumors
Study: 25062651
Drug: Weight-based insulin
Normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight-based insulin glargine dose titration regimen
Study: 25062651
Drug: Glucose level-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose level-based insulin glargine dose titration regimen
Study: 25062651
Drug: Current dose-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current dose-based insulin glargine dose titration regimen
Study: 21980058
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 μg)
Study: 21980058
Drug: Salmeterol/Fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone propionate (50/250 μg)
Study: 21980058
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (250 μg)
Study: 17877164
Drug: A +
Normalized name: Vital E- A + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: A + C vaccine
Study: 2645508
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Tetrazepam, Baclofen, Tizanidine)
Study: 30352770
Drug: Biomechanical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomechanical therapy with a foot-worn biomechanical device
Study: 29071986
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy combined with nutrition consultation
Study: 25892145
Drug: Methotrexate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (40 mg/m2 per week)
Study: 24165884
Drug: Etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 200 mg bid for 14 days with cocktail on days 1 and 14
Study: 24165884
Drug: Etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 200 mg bid for 12 days with digoxin on day 8
Study: 22852050
Drug: Carbohydrate-only (CHO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-only (CHO; 75 g per beverage)
Study: 22852050
Drug: High-carbohydrate/low-protein (HCLP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate/low-protein (HCLP; 45 g CHO, 25 g Pro, 0.5 g fat)
Study: 22852050
Drug: Low-carbohydrate/high-protein (LCHP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate/high-protein (LCHP; 8 g CHO, 55 g Pro, 4 g fat)
Study: 22852050
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (CHO, HCLP, LCHP)
Study: 17519069
Drug: LOP/SIM 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOP/SIM 2 mg/125 mg
Study: 17519069
Drug: LOP 2
Normalized name: CAMPHOR (SYNTHETIC) 4 g in 100 mL TOPICAL OIL [WONG LOP KONG MEDICATED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOP 2 mg
Study: 17519069
Drug: SIM 125
Normalized name: Bicarsim 125 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIM 125 mg
Study: 14688160
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 microg 3 h prior to SE)
Study: 14688160
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 microg 3 h prior to SE)
Study: 9260007
Drug: Tramadol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (10 mg PCA bolus)
Study: 9260007
Drug: Tramadol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol + Droperidol (10 mg tramadol + 0.1 mg droperidol PCA bolus)
Study: 3440104
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 5 g orally at hourly intervals for 7 h
Study: 23354809
Drug: Piperacillin/tazobactam dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam dosing strategy of 44.44/5.56 mg/kg/dose every 8 or 12 hours
Study: 18353242
Drug: HBIG injection
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBIG injection every four weeks until labor (experimental group with HBsAg positive)
Study: 18353242
Drug: HBIG injection
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBIG injection every four weeks until labor (experimental group with both HBsAg and HBeAg positive)
Study: 12890165
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb761) 120 mg/day for 14 days
Study: 12890165
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb761) 240 mg/day for 14 days
Study: 12890165
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb761) 480 mg/day for 14 days
Study: 10976194
Drug: Lansoprazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I)
Study: 10976194
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II)
Study: 2878490
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with two injections a day (CTh)
Study: 30036854
Drug: Injectable disease-modifying
Normalized name: modified fluid gelatins Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable disease-modifying therapies (iDMTs)
Study: 22297398
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous zoledronic acid (ZOL)
Study: 11481623
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 6 MU daily of interferon alfa 2b plus 800 mg of ribavirin
Study: 11481623
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with 6 MU daily of IFN‐alpha2b
Study: 11481623
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with twice‐daily intravenous administration with 3MU of IFN‐beta
Study: 11481623
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with daily intravenous administration with 6 MU of IFN‐beta
Study: 8001404
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide with oxygen inhalation
Study: 8132369
Drug: Daily antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antibiotic prophylaxis with Phenoxymethylpenicillin (or erythromycin for penicillin-allergic patients)
Study: 25851632
Drug: EVE/BEV (everolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVE/BEV (everolimus 10 mg/day + bevacizumab 10 mg/kg every 2 weeks)
Study: 25851632
Drug: IFN/BEV (interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN/BEV (interferon 9 MIU 3 times/week + bevacizumab 10 mg/kg every 2 weeks)
Study: 23646475
Drug: Xuebijing Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing Injection (XI), intravenously injected with 100 mL QI in 100 mL normal saline, twice daily for seven days
Study: 21494043
Drug: Real-time group
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time group with real-time viewer and polyethylene glycol (500 ml) or metoclopramide (10 mg) if capsule in stomach.
Study: 21494043
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group without preparation.
Study: 19138700
Drug: Rod reaction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rod reaction times plotted against the spatial luminance ratio (L(max)/L(min)) between the stimulus and its background.
Study: 17966177
Drug: Ketoconazole cream
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole cream (n=210)
Study: 17966177
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream (n=105)
Study: 11473852
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia plus a titrated IV propofol infusion (LA/PI)
Study: 28523945
Drug: Menopause-related hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menopause-related hormone therapy (MHT)
Study: 24311403
Drug: Corticosteroid administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid administration
Study: 21205623
Drug: Cisatracurium 20
Normalized name: cisatracurium 200 MG per 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 20 µg kg(‐1), followed by four incremental 10 µg kg(‐1) doses, and the remainder of 100 µg kg(‐1)
Study: 18206256
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of treatments
Study: 18206256
Drug: Database of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Database of treatment parameters
Study: 11513308
Drug: slow-release caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow-release caffeine (300 mg)
Study: 11513308
Drug: melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: melatonin (5 mg)
Study: 9756109
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) monotherapy
Study: 3180201
Drug: Flunarizine 20
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 20 mg by slow intravenous injection
Study: 27967328
Drug: Pharmacogenomic (PG)
Normalized name: PG
DrugBank: 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (DB11331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenomic (PG) dosing algorithm
Study: 25845302
Drug: Non-absorbable 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-absorbable 15 × 10 cm anatomical mesh fixed with 2 ml fibrin sealant (Group 4)
Study: 20977679
Drug: FTC/TDF (200/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC/TDF (200/300 mg) + BILR 355/r (150/100 mg)
Study: 20977679
Drug: BILR 355/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILR 355/r (150/100 mg)
Study: 19875408
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (Ferinject) 200 mg iron i.v. weekly until iron repletion, then monthly until Week 24
Study: 14756638
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of excimer laser treatment and topical tacrolimus 0.1% ointment
Study: 3535811
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg at night
Study: 3535811
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg at night and Naproxen 500 mg twice daily
Study: 28993180
Drug: Single-tablet regimen
Normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-tablet regimen of darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg taken once per day for 48 weeks
Study: 28993180
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen of boosted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate
Study: 28993180
Drug: Single-tablet regimen
Normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
Study: 26625418
Drug: Perturbations delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perturbations delivered along the Medio‐Lateral (ML) direction
Study: 25406652
Drug: CBCT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBCT group - mini-implants placed using CBCT data
Study: 25406652
Drug: RVG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVG group - mini-implants placed using two-dimensional digital radiographs and a custom made guide
Study: 15676050
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl 100 microg
Study: 15676050
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl 200 microg
Study: 12593177
Drug: Inhaled long-acting
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled long-acting beta 2-mimetics and steroids
Study: 10511331
Drug: Severe protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe protein restriction diet (0.30 g/kg/day) supplemented with ketoanalogues (Group A)
Study: 10511331
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein restriction diet (0.65 g/kg/day) (Group B)
Study: 6240785
Drug: Thiamphenicol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamphenicol (2.5 g perorally)
Study: 22832068
Drug: Fusion model
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fusion model (combination of ERP and power features)
Study: 10320179
Drug: Clonidine 150
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 150 microg in 15 mL of saline (Group Clonidine)
Study: 10320179
Drug: Saline 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 15 mL (Group Saline)
Study: 10320179
Drug: Bupivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 15 mL (Group Bupivacaine)
Study: 1859757
Drug: Thiopentone and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone and Propofol combination
Study: 6981173
Drug: Intravenous trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous trimethoprim (TMP) 150 mg/m2 and sulfamethoxazole (SMZ) 750 mg/m2 every 8 hr
Study: 6981173
Drug: Intravenous trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous trimethoprim (TMP) and sulfamethoxazole (SMZ)
Study: 31526557
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous vitamin C (1,500 mg every 6 hours)
Study: 12029403
Drug: Prone Positioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prone Positioning (PP) for 4 hours once daily until patients could sit in an armchair
Study: 9617717
Drug: Sinemet CR
Normalized name: Sinemet CR
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sinemet CR (chronic release formulation of levodopa/carbidopa)
Study: 1779440
Drug: Aqueous acupuncture
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous acupuncture (2 to 5 ml of 20% glucose solution injected into Ho‐Ku (LI 4) and Yang‐Ling‐Chuan (GB 34))
Study: 30592371
Drug: Everolimus (EVR)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVR) 1.5 mg twice daily starting on day 8
Study: 28585903
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg twice daily for 30 days
Study: 28585903
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg daily for 30 days
Study: 26206864
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus higher-intensity, progressive aerobic exercise (S+PAE)
Study: 26206864
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus lower-intensity, non-progressive exercise (S+NPE)
Study: 18854549
Drug: Two-weekly oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two-weekly oxaliplatin 85 mg/m(2) + continuous intravenous infusion (CIV) of 5‐FU without LV or two‐weekly bolus and CIV 5‐FU + LV (LV5FU2)
Study: 17407646
Drug: Analogue basal-bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analogue basal-bolus insulin (insulin detemir plus insulin aspart)
Study: 17407646
Drug: Human basal-bolus
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human basal-bolus insulin (Neutral Protamine Hagedorn plus human soluble insulin)
Study: 11136280
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg for 2 weeks (Group A)
Study: 11136280
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg for 2 weeks (Group B)
Study: 30770244
Drug: Lidocaine/Ketorolac combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/Ketorolac combination (1.5 mg/kg lidocaine and 30 mg ketorolac)
Study: 30511473
Drug: Lamotrigine extended-release
Normalized name: Lamotrigine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine extended-release formulation (test group)
Study: 17467513
Drug: Valsartan (40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (40-160 mg per day)
Study: 17467513
Drug: Control (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (other treatment without angiotensin receptor blockers)
Study: 15011856
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy (diluted adrenalin 1:10,000 plus polidocanol 1%, group B)
Study: 11724223
Drug: Tramadol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (75 mg)
Study: 11724223
Drug: APAP (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: APAP (650 mg)
Study: 8484506
Drug: Intranasal meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal meperidine (6 sprays, 27 mg)
Study: 8484506
Drug: Intravenous meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine (6 mL, 27 mg)
Study: 8484506
Drug: Intranasal NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal NaCl 0.9% (6 sprays)
Study: 8484506
Drug: Intravenous NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous NaCl 0.9% (6 mL)
Study: 2892582
Drug: Bevantolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol (200 mg) + Hydrochlorothiazide (25 mg)
Study: 26404844
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Oxytocin (OT) administration (40 IU)
Study: 24394704
Drug: Flavanol-rich soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanol-rich soluble cocoa product (7.5 g per serving, 2 servings per day, providing 45.3 mg flavanols per day)
Study: 22426371
Drug: MF59-adjuvanted trivalent
Normalized name: Influenza, adjuvanted, trivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted trivalent influenza subunit vaccine Fluad (®)
Study: 22426371
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of MF59 (®)
Study: 16640103
Drug: Indinavir (IDV)
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir (IDV) 800 mg three times daily with zidovudine (AZT)/lamivudine (3TC) twice daily
Study: 16640103
Drug: Indinavir/ritonavir (IDV/RTV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir/ritonavir (IDV/RTV) 800/100 mg twice daily with zidovudine (AZT)/lamivudine (3TC) twice daily
Study: 12894981
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of the discriminant with the level of suspicion values of the radiologist